Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

APASL Covid-19 Task Force

doi:10.1007/s12072-020-10054-w

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

APASL Covid-19 Task Force

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

Abstract

Background: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. Aims: In order to enhance scientific information interflow in the arena of liver diseases in Asia–Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. Methods: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia–Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. Conclusions: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.

Original language	English
Pages (from-to)	415-428
Number of pages	14
Journal	Hepatology International
Volume	14
Issue number	4
DOIs	https://doi.org/10.1007/s12072-020-10054-w
Publication status	Published - 1 Jul 2020

Keywords

ACLF
APASL
CLD
COVID-19
DDLT
Guidance
Hepatology
Immunosuppression
LDLT
Liver injury

Access to Document

10.1007/s12072-020-10054-w

Cite this

@article{c166b6efecb8456faacebfe8b1dc8b46,

title = "Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations",

abstract = "Background: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. Aims: In order to enhance scientific information interflow in the arena of liver diseases in Asia–Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. Methods: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia–Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. Conclusions: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.",

keywords = "ACLF, APASL, CLD, COVID-19, DDLT, Guidance, Hepatology, Immunosuppression, LDLT, Liver injury",

author = "{APASL Covid-19 Task Force} and Cheng Gregory and Gani Rino and Guan Richard and Hasmik Ghazinyan and Kadir Dokmeci and Kanda Tatsuo and Kao Jia-Horng and Lau George and Lesmana Laurentius and Merican Ismail and Omata Masao and Payawal Diana and Piratvisuth Teerha and Sarin, {S. K.} and Sharma Manoj and Sollano Jose and Strasser Simone and Tanwandee Tawesak and Wasim Jafri and Wei Lai and Mo, {Yang Jin} and Yokosuka Osamu and George Lau and Manoj Sharma",

note = "Publisher Copyright: {\textcopyright} 2020, Asian Pacific Association for the Study of the Liver.",

year = "2020",

month = jul,

day = "1",

doi = "10.1007/s12072-020-10054-w",

language = "English",

volume = "14",

pages = "415--428",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic

T2 - APASL expert panel consensus recommendations

AU - APASL Covid-19 Task Force

AU - Gregory, Cheng

AU - Rino, Gani

AU - Richard, Guan

AU - Ghazinyan, Hasmik

AU - Dokmeci, Kadir

AU - Tatsuo, Kanda

AU - Jia-Horng, Kao

AU - George, Lau

AU - Laurentius, Lesmana

AU - Ismail, Merican

AU - Masao, Omata

AU - Diana, Payawal

AU - Teerha, Piratvisuth

AU - Sarin, S. K.

AU - Manoj, Sharma

AU - Jose, Sollano

AU - Simone, Strasser

AU - Tawesak, Tanwandee

AU - Jafri, Wasim

AU - Lai, Wei

AU - Mo, Yang Jin

AU - Osamu, Yokosuka

AU - Lau, George

AU - Sharma, Manoj

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Background: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. Aims: In order to enhance scientific information interflow in the arena of liver diseases in Asia–Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. Methods: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia–Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. Conclusions: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.

AB - Background: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. Aims: In order to enhance scientific information interflow in the arena of liver diseases in Asia–Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. Methods: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia–Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. Conclusions: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.

KW - ACLF

KW - APASL

KW - CLD

KW - COVID-19

KW - DDLT

KW - Guidance

KW - Hepatology

KW - Immunosuppression

KW - LDLT

KW - Liver injury

UR - http://www.scopus.com/inward/record.url?scp=85085356791&partnerID=8YFLogxK

U2 - 10.1007/s12072-020-10054-w

DO - 10.1007/s12072-020-10054-w

M3 - Article

C2 - 32447721

AN - SCOPUS:85085356791

SN - 1936-0533

VL - 14

SP - 415

EP - 428

JO - Hepatology International

JF - Hepatology International

IS - 4

ER -

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this